MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — making it a mitochondria-derived peptide (mitokine). It regulates metabolic homeostasis, insulin sensitivity, and cellular stress resistance. Animal studies demonstrate exercise-mimicking effects and lifespan extension, establishing MOTS-c as a key focus in longevity and metabolic research.
Mechanism of Action
MOTS-c activates AMPK (AMP-activated protein kinase), the master energy sensor of the cell. AMPK activation inhibits anabolic energy-consuming pathways, stimulates glucose uptake, drives fatty acid oxidation, and promotes mitochondrial biogenesis — collectively mimicking the molecular effects of exercise.
MOTS-c translocates from mitochondria to the nucleus in response to metabolic stress, where it functions as a transcriptional regulator of stress response genes. This mitochondria-to-nucleus signalling pathway is thought to coordinate whole-cell and whole-organism metabolic adaptations.
In aged mice, MOTS-c levels decline markedly. Administration of exogenous MOTS-c restores metabolic flexibility, reduces adiposity, and has been shown to extend lifespan in multiple rodent ageing models — supporting a causal role in age-related metabolic decline.
Research Evidence
MOTS-c research has expanded rapidly since its discovery in 2015. Human plasma MOTS-c levels correlate inversely with age and with metabolic disease risk, supporting its physiological relevance in human ageing.
MOTS-c: A Mitochondrial-Encoded Regulator of the Methionine Cycle
Discovery paper: MOTS-c regulates the methionine cycle and folate-SHMT axis, impairs de novo purine synthesis, and activates AMPK — producing insulin sensitisation and obesity resistance in mice.
MOTS-c Extends Lifespan in Male Mice on a High-Fat Diet
Aged male mice receiving MOTS-c for 2 months showed improved exercise capacity, muscle function, and reduced all-cause mortality — phenocopying exercise training in aged sedentary mice.
Typical Research Protocol
MOTS-c research protocols vary widely. Some use daily low-dose (2–5mg/day) while others use 3x weekly higher-dose approaches. Human optimal dosing is not established.
Safety Profile
Reported Side Effects
- Injection site redness
- Mild fatigue (first week)
- Increased appetite (possible)
Contraindications
- Pregnancy (no data)
- Insulin-dependent diabetes (AMPK effects on glucose — monitor closely)
- Active malignancy (AMPK has pro-survival roles in some cancers)
Published Research
262 indexed PubMed papers reference MOTS-c. The 20 most recent are listed below.
- MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis.
-
Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.
PMID 42752426 Open on PubMed →
- Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications.
- Correction: Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.
- AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition.
- Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review.
- MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential.
- Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming.
- MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide.
- Mitochondrial dysfunction in ARDS: unraveling the regulatory networks and therapeutic opportunities.
- Emerging regulators of human physiology and disease; sORF-encoded microproteins.
- Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy.
- Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells.
- Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.
- Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study.
- MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.
- MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.
- MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury.
- Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
- Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.
Common Research Stacks
Frequently Asked Questions
Is MOTS-c an exercise mimetic?
In animal studies, MOTS-c phenocopies many molecular effects of aerobic exercise — AMPK activation, improved insulin sensitivity, enhanced fat oxidation, and mitochondrial biogenesis. Whether it replicates all exercise benefits in humans is not yet established. It is studied as a potential intervention for populations unable to exercise (frailty, disability) as well as an enhancer of exercise adaptations.
How does MOTS-c differ from Humanin?
Both are mitochondria-derived peptides (MDPs) encoded in mitochondrial DNA, but they have distinct mechanisms. MOTS-c is encoded by the 12S rRNA gene and primarily regulates metabolic homeostasis via AMPK activation. Humanin is encoded by the 16S rRNA gene and focuses on neuroprotection, insulin signalling, and cardiovascular protection. They have complementary rather than overlapping biology.
Does MOTS-c have cardiovascular benefits?
Preclinical research suggests MOTS-c has cardioprotective properties — it reduces oxidative stress in cardiomyocytes, improves vascular endothelial function, and may reduce atherosclerotic plaque formation via AMPK-driven anti-inflammatory effects. Human cardiovascular data is not yet available, but the mechanistic basis for cardiac benefits is well-supported in animal models.
What is the relationship between MOTS-c and longevity?
Plasma MOTS-c levels decline with age in humans and are lower in individuals with age-related metabolic diseases. In Japanese supercentenarians (100+ years), specific mitochondrial polymorphisms associated with higher MOTS-c production are enriched compared to the general population, suggesting genetic MOTS-c upregulation contributes to exceptional longevity. This epidemiological link strengthens the mechanistic case for MOTS-c as a longevity-relevant target.
Does MOTS-c improve insulin sensitivity?
Yes — insulin sensitisation is one of MOTS-c's most robust effects. Through AMPK activation and methionine cycle regulation, MOTS-c improves glucose uptake in skeletal muscle and reduces hepatic glucose output. In diet-induced obese mouse models, MOTS-c administration normalised blood glucose, reduced insulin resistance markers, and improved metabolic flexibility comparable to exercise training interventions.
Key Research References
- Lee C et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab.
- Reynolds JC et al. (2021). MOTS-c is an exercise-induced mitochondrial encoded regulator. Nat Commun.
Explore more Longevity research compounds
Browse Longevity →